Navigating 4 Analyst Ratings For Sutro Biopharma
Portfolio Pulse from Benzinga Insights
Sutro Biopharma (NASDAQ:STRO) received mixed analyst ratings with a shift towards a more cautious outlook over the past three months. The average 12-month price target was adjusted to $11.75, marking a 7.26% decrease from the previous target. Analysts from Oppenheimer, Wedbush, JMP Securities, and HC Wainwright & Co. provided updates, with some maintaining and others lowering their price targets. The company's financial performance shows a significant revenue decline and challenges in ROE and ROA, despite efficient cost management indicated by its net margin.
March 27, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sutro Biopharma received mixed analyst ratings, with a revised average 12-month price target of $11.75. The company faces significant financial challenges, including a notable revenue decline and underperformance in ROE and ROA.
The mixed analyst ratings, combined with the downward revision of the price target and the company's financial challenges, suggest a cautious or negative outlook for STRO in the short term. The significant revenue decline and underperformance in key financial metrics could impact investor sentiment negatively.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100